Arkolith/Stocks/CRESCENT BIOPHARMA, INC.

CRESCENT BIOPHARMA, INC.

Cross-source read

No active 13F manager changed its position in CRESCENT BIOPHARMA, INC. last quarter. Over the last 180 days, 1 insider bought and 7 insiders sold, a net +$10.9M in open-market trades.

Tracked 13F holders
0
13F value (tracked)
$0
Smart-money readMixed
Net sellingNet buying
Funds · active managers, latest 13F
0 adding · 0 trimming
Insiders · Form 4 open-market, 180d
1 buying · 7 selling · +$10.9M
US House · STOCK Act, 180d
0 buying · 0 selling

The legs disagree, or only one of them leans.

Who owns CRESCENT BIOPHARMA, INC.?

0 tracked 13F filers · ranked by shares held

Not held in any tracked 13F filing yet.

Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.

Insider activity (Form 4)

Full insider page →
Buys · 180d
$12.4M
1 insider
Sells · 180d
$1.5M
7 insiders
Net · 180d
$10.9M
17 open-market transactions
DateInsiderRoleActionSharesValue
Sep 18, 2026Brumm Joshua TChief Executive Officer, DirectorSell (S)8K$131K
Sep 18, 2026McNeill JonathanPresident and COOSell (S)4K$64K
Sep 16, 2026Brumm Joshua TChief Executive Officer, DirectorSell (S)2K$29K
Sep 16, 2026Pinkas JanChief Scientific OfficerSell (S)658$12K
Sep 16, 2026Scalzo Richard WilliamChief Financial OfficerSell (S)568$10K
Sep 16, 2026Lynch RyanSee RemarksSell (S)240$4K
Sep 16, 2026McNeill JonathanPresident and COOSell (S)731$13K
Sep 16, 2026Im Ellie EunkyungChief Medical OfficerSell (S)623$11K
Sep 16, 2026Bispham Barbara HarlinSee RemarksSell (S)620$11K
Jul 16, 2026Fairmount Funds Management LLCDirector, 10% OwnerBuy (P)853K$12.4M
Jun 22, 2026McNeill JonathanPresident and COOSell (S)21K$370K
Jun 22, 2026Im Ellie EunkyungChief Medical OfficerSell (S)1K$22K

Do institutions, insiders and Congress agree?

Mixed signals

Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.

SEC EDGAR 13F + Form 4 + US House STOCK Act{ }get_ticker_confluence · API & MCP

Signals by source

Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive

SourceBuyingSellingNet
13F funds
Top 100 holders by value, passive included; the hero counts active managers only
00–
Insiders
Form 4 open-market
17+$10.9M
US House
STOCK Act trades
00$0

Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.

Recent filings

15 most recent

Keep exploring

Connected entities for CRESCENT BIOPHARMA, INC.

More on CRESCENT BIOPHARMA, INC.

Browse more

All tracked stocks A–ZCRESCENT BIOPHARMA, INC. insider filings13F funds A–Z
Build

Ask your agent what changed in CRESCENT BIOPHARMA, INC.

This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.

Get a key Compare plansWorkflow docs
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/stocks/GLYC/capital-change-brief"
Ask your agent
Use Arkolith's capital_change_brief for CRESCENT BIOPHARMA, INC..
Tell me what changed, whether insider activity
corroborates it, and cite the SEC evidence.

13F holdings + Form 4 insider transactions + the live filing stream, joined for GLYC. Filings are public domain, sourced to SEC EDGAR.